PARTIALLY HYDROLYZED GUAR GUM INTAKE AMELIORATES CONSTIPATION, IMPROVES NUTRITIONAL STATUS AND REDUCES INDOXYLSULFURIC ACID IN DIALYSIS PATIENTS.
PARTIALLY HYDROLYZED GUAR GUM INTAKE AMELIORATES CONSTIPATION, IMPROVES NUTRITIONAL STATUS AND REDUCES INDOXYLSULFURIC ACID IN DIALYSIS PATIENTS.
复制标题
摄入部分水解瓜尔胶可改善透析患者的便秘、改善营养状况并减少吲哚基硫酸。
DOI：
10.1016/j.krcp.2012.04.470
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
S. Sakai
中科院分区：
文献类型：
--
作者：
H. Maeda;T. Uemura;M. Nasu;Natsumi Iwata;Junko Yoshimura;S. Sakai
透析患者常发生便秘和肠道细菌植物群的变化。吲哚硫酸（IS）水平随着肾小球滤过率降低而升高，肾衰竭患者IS水平较高。升高的IS也是由改变的肠道植物群引起的吲哚增加引起的（Takayama等，Am J Kidney Dis.2003）。我们研究了施用部分水解的瓜尔胶（PHGG）（Sunfiber：Taiyokagaku Co.，有限公司、日本）改善便秘，改善透析患者的营养状况，同时降低IS水平。35例维持性透析患者（平均年龄，71 ± 9岁;男性/女性= 22/13）摄入PHGG（10 g/天）6周。使用改良的便秘评估量表-长期（日语版）对PHGG摄入前后的排便进行评分。根据老年营养风险指数（GNRI）评估PHGG摄入前后的营养状况。测定8例口服PHGG 24周的患者IS，并与8例未服用PHGG的患者进行比较。便秘评分从7.9降至5.0（p <0.01），GNRI从95.0 ± 5.0增至95.9 ± 5.7（p <0.05），反映便秘改善和营养状况改善。计算摄入PHGG前后IS的比值，分析IS的变化幅度。未服用PHGG的患者的比值为1.2 ± 0.3，即IS升高，而服用PHGG的患者的比值显著降低（0.8 ± 0.3，p <0.05）。我们的研究结果表明，PHGG的消费，以改善便秘和改善营养状况，并继续摄入减少IS，透析患者。
Dialysis patients often develop constipation and changes in intestinal bacterial flora. Indoxylsulfuric acid (IS) levels rise as glomerular filtration decreases, and patients with renal failure have high IS. Elevated IS is also caused by increased indole due to altered intestinal flora (Takayama et al, Am J Kidney Dis. 2003). We investigated whether administering partially hydrolyzed guar gum (PHGG) (Sunfiber: a product of Taiyokagaku Co., Ltd., Japan) ameliorates constipation and improves nutritional status in dialysis patients, while decreasing IS levels. Thirty-five patients on maintenance dialysis (mean age, 71 ± 9; male/female= 22/13) ingested PHGG (10 g/day) for 6 weeks. Defecation was scored before and after PHGG intake using a modified Constipation Assessment Scale-Long Term (Japanese version). Nutritional status was rated according to the Geriatric Nutritional Risk Index (GNRI) before and after PHGG intake. IS was measured in 8 patients taking PHGG orally for 24 weeks, for comparison with those in 8 patients not on PHGG. Constipation scores decreased from 7.9 to 5.0 (p <.01) and GNRI increased from 95.0 ± 5.0 to 95.9 ± 5.7 (p <.05), reflecting amelioration of constipation and improved nutritional status. The ratio of IS after to that before PHGG intake was calculated to analyze the magnitude of IS change. The ratio in patients not on PHGG was 1.2 ± 0.3, i.e. IS rose, while that in patients taking PHGG was significantly reduced (0.8 ± 0.3, p <.05). Our results indicate PHGG consumption to ameliorate constipation and improve nutritional status, and that continued intake reduces IS, in dialysis patients.